Homozygous Familial Hypercholesterolemia (HoFH) is a rare life-threatening genetic disorder characterized by markedly elevated levels of low-density lipoprotein cholesterol (LDL-C) in the blood and premature and progressive cardiovascular disease.
FarmaMondo was pleased to host a successful advisory board on HoFH in Hong Kong a few days ago. The discussions between 7 local experts and international speakers were very fruitful and insightful. They will give us a clearer vision of how best to support patients with HoFH.
As a next step, we will build on the experts’ advice to improve diagnosis and unlock access to an advanced treatment option for patients with LDL-C in Hong Kong.
We use cookies that are strictly necessary to operate this website.
We also use optional cookies to improve your accessibility to our website and its functionality, to analyse and track your use of our website and to give you the best possible user experience.
You will need to activate optional cookies. For more detailed information on our use of cookies on this website, please read our Cookie Policy, which also explains how to customise your Cookies settings.
You can also accept all our cookies or customise your Cookies settings by clicking on the buttons provided below.
This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
FarmaMondo was pleased to host a successful advisory board on HoFH in Hong Kong a few days ago. The discussions between 7 local experts and international speakers were very fruitful and insightful. They will give us a clearer vision of how best to support patients with HoFH.
As a next step, we will build on the experts’ advice to improve diagnosis and unlock access to an advanced treatment option for patients with LDL-C in Hong Kong.